Table 2. Demographic and baseline characteristics of the cohort on the basis of achieved on-treatment target blood pressure control.
|
Good control |
Poor control |
|||||||
|---|---|---|---|---|---|---|---|---|
| Benidipine plus ARB (n=592) | Benidipine plus BB (n=577) | Benidipine plus TD (n=564) | P-value | Benidipine plus ARB (n=439) | Benidipine plus BB (n=398) | Benidipine plus TD (n=431) | P-value | |
| Sex, male | 297 (50.2) | 287 (49.7) | 288 (51.1) | 0.901 | 226 (51.5) | 200 (50.3) | 210 (48.7) | 0.718 |
| Age, years | 62.5±10.3 | 63.4±10.5 | 63.8±10.3 | 0.093 | 63.8±11.0 | 63.3±11.0 | 63.1±11.1 | 0.675 |
| BMI, kg m−2 | 24.6±3.4 | 24.4±3.4 | 24.4±3.4 | 0.661 | 24.8±3.4 | 24.9±3.4 | 24.4±3.3 | 0.099 |
| Systolic BP, mm Hg | 151.0±10.6 | 151.4±9.6 | 151.7±10.2 | 0.525 | 157.6±12.2 | 156.8±11.7 | 157.4±13.2 | 0.656 |
| Diastolic BP, mm Hg | 88.5±9.2 | 88.0±9.4 | 87.9±9.3 | 0.531 | 89.7±10.4 | 89.2±9.9 | 89.3±10.3 | 0.736 |
| Heart rate, beat per min | 73.9±11.1 | 74.7±10.9 | 73.3±11.0 | 0.140 | 74.1±11.2 | 73.8±11.1 | 75.4±12.1 | 0.146 |
| Previous CV desease | 66 (11.1) | 63 (10.9) | 78 (13.8) | 0.242 | 67 (15.3) | 49 (12.3) | 52 (12.1) | 0.305 |
| Diabetes | 67 (11.3) | 65 (11.3) | 72 (12.8) | 0.671 | 78 (17.8) | 74 (18.6) | 71 (16.5) | 0.720 |
| Dyslipidemia | 238 (40.2) | 235 (40.7) | 229 (40.6) | 0.982 | 164 (37.4) | 159 (39.9) | 192 (44.5) | 0.092 |
| Current smoking | 234 (39.5) | 220 (38.1) | 234 (41.5) | 0.507 | 168 (38.3) | 161 (40.5) | 157 (36.4) | 0.492 |
| Anti-hypertensive agents | 462 (78.0) | 456 (79.0) | 444 (78.7) | 0.915 | 367 (83.6) | 331 (83.2) | 363 (84.2) | 0.918 |
| Benidipine | 364 (61.5) | 363 (62.9) | 349 (61.9) | 0.875 | 287 (65.4) | 262 (65.8) | 286 (66.4) | 0.954 |
| Other CCB | 65 (11.0) | 60 (10.4) | 58 (10.3) | 0.918 | 56 (12.8) | 50 (12.6) | 55 (12.8) | 0.995 |
| ARB | 47 (7.9) | 48 (8.3) | 47 (8.3) | 0.962 | 47 (10.7) | 47 (11.8) | 49 (11.4) | 0.878 |
| ACE inhibitor | 15 (2.5) | 11 (1.9) | 10 (1.8) | 0.623 | 2 (0.5) | 12 (3.0) | 3 (0.7) | 0.002 |
| BB | 13 (2.2) | 20 (3.5) | 23 (4.1) | 0.180 | 11 (2.5) | 15 (3.8) | 10 (2.3) | 0.398 |
| Diuretics | 3 (0.5) | 4 (0.7) | 6 (1.1) | 0.538 | 7 (1.6) | 4 (1.0) | 7 (1.6) | 0.700 |
| α-Blocker | 2 (0.3) | 7 (1.2) | 2 (0.4) | 0.101 | 3 (0.7) | 3 (0.8) | 0 (0.0) | 0.209 |
| Concomitant medication | ||||||||
| Anti-platelets | 43 (7.3) | 46 (8.0) | 49 (8.7) | 0.670 | 47 (10.7) | 27 (6.8) | 29 (6.7) | 0.050 |
| Lipid-lowering agents | 132 (22.3) | 125 (21.7) | 121 (21.5) | 0.936 | 87 (19.8) | 82 (20.6) | 92 (21.3) | 0.856 |
| Statin | 106 (17.9) | 103 (17.9) | 94 (16.7) | 0.824 | 69 (15.7) | 68 (17.1) | 66 (15.3) | 0.769 |
| Anti-diabetic agents | 31 (5.2) | 28 (4.9) | 38 (6.7) | 0.343 | 40 (9.1) | 41 (10.3) | 34 (7.9) | 0.481 |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, β-blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CV, cardiovascular.
Data are shown as the number of patients (%) or mean±s.d. Differences in the proportions between the good and poor control groups were analyzed using the χ2-test or one-way analysis of variance.